Looking to expand your partner network with leading companies like Glycotope? Consider joining Inpart's global network for free.
News and Trends 13 Dec 2022
Therabest and Glycotope to assess breast cancer combination treatment
Therabest USA. Inc, Therabest Korea and Glycotope GmbH have signed an agreement to assess the clinical development of Therabest’s EiNK (enhanced iPSC-derived NK) cell therapy, TB-100, in combination with Glycotope’s immuno-cytokine, GT-00AxIL15 in triple-negative breast cancer (TNBC) patients. NK (natural killer) cell therapies from various cell sources have demonstrated exciting results in early clinical trials […]
